News Chart 89bio, Inc.

Equities

ETNB

US2825591033

Real-time Estimate Cboe BZX Other stock markets 01:15:59 2024-05-15 pm EDT			5-day change	1st Jan Change
9.53 ^USD	+4.84%		+5.76%	-14.50%

May. 14	89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	CI
May. 10	HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating	MT

c854ac264ece8273419c8.dAjscD5dxHWm4dUMjtbDCFA-BmWOUOBWkOTfN70ydkw.AiXUSVsJhjzP1YpZ1LmabRdSZDbNF6gJ6p6UZvd8NS4nO6MYc2qIQdOvnA~01e3ddf6b0949eea77bcf8c4b792f21d